structureguid
design
use
gener
seri
noncoval
inhibitor
nanomolar
potenc
papainlik
proteas
plpro
sar
coronaviru
cov
number
inhibitor
exhibit
antivir
activ
sarscov
infect
vero
cell
broaden
specif
toward
homolog
enzym
human
coronaviru
select
cytotox
studi
establish
prefer
coronavir
enzym
homolog
human
deubiquitin
enzym
dub
signific
cytotox
vero
cell
line
observ
xray
structur
analys
inhibitorbound
crystal
structur
reveal
subtl
differ
bind
mode
initi
benzodioxolan
lead
potent
analogu
featur
monofluoro
substitut
para
meta
posit
benzyl
ring
respect
final
less
lipophil
bi
amid
methoxypyridin
exhibit
significantli
improv
metabol
stabil
viabl
candid
advanc
vivo
studi
year
pandem
caus
sar
sever
acut
respiratori
syndrom
coronaviru
cov
anticoronavir
regimen
develop
treatment
sarscov
human
coronavirus
hcov
infect
sarscov
establish
caus
agent
fatal
global
outbreak
respiratori
diseas
human
result
casefat
rate
cfr
octob
center
diseas
control
prevent
cdc
ad
sarscov
select
agent
list
depart
health
human
servic
hh
among
mani
aspect
make
sarscov
potenti
threat
human
popul
lack
effect
vaccin
anticoronavir
drug
signific
impact
classif
select
agent
howev
even
extens
prevent
measur
reemerg
sarscov
virul
human
coronavirus
pose
continu
threat
power
remind
well
fatal
repercuss
interspeci
transmiss
potenti
cov
brought
forefront
septemb
emerg
new
sarslik
respiratori
viru
previous
term
hcovemc
design
middl
east
respiratori
syndrom
coronaviru
merscov
case
sarscov
merscov
like
zoonot
origin
close
relat
bat
coronavirus
betacoronaviru
genu
group
reminisc
initi
stage
sarscov
pandem
global
travel
contribut
spread
mer
coronaviru
total
laboratoryconfirm
case
cfr
infect
individu
display
sarslik
symptom
includ
sever
respiratori
infect
sri
sometim
exhibit
acut
renal
failur
uniqu
signatur
mer
infect
today
total
human
coronavirus
known
sarscov
merscov
recogn
highli
pathogen
potenti
humantohuman
transmiss
without
efficaci
antivir
agent
vaccin
prevent
current
emerg
coronavirus
continu
reli
strongli
public
health
measur
contain
outbreak
therefor
research
toward
develop
anticoronavir
drug
continu
paramount
import
develop
anticoronavir
drug
challeng
although
number
coronavir
protein
identifi
potenti
drug
target
develop
drug
candid
compromis
gener
lack
antivir
data
biolog
evalu
done
facil
select
agent
certif
laboratori
us
two
promis
drug
target
sarscovencod
cystein
proteas
chymotrypsinlik
proteas
plpro
papainlik
proteas
plpro
addit
play
essenti
role
viru
replic
propos
key
enzym
pathogenesi
sarscov
wellestablish
role
plpro
enzymat
activ
includ
process
viral
polyprotein
deubiquitin
remov
ubiquitin
deisgyl
remov
hostcel
protein
last
two
enzymat
activ
result
antagon
host
antivir
innat
immun
respons
sarscov
plpro
inhibitor
compound
h
previous
identifi
lab
via
highthroughput
screen
ht
low
micromolar
inhibitori
potenc
minim
associ
cytotox
sarscovinfect
vero
cell
therefor
viabl
lead
develop
drug
candid
figur
detail
report
synthesi
biolog
evalu
inhibitor
xray
structur
complex
sarscov
plpro
previous
describ
compound
share
number
chemic
structur
featur
figur
includ
presenc
naphthyl
group
adjac
stereogen
center
contain
methyl
group
nitrogencent
hydrogen
bond
hbond
donor
physiolog
ph
addit
lead
share
carboxamid
linker
opposit
orient
differenti
substitut
benzenoid
group
relationship
sar
shown
inhibitor
subtyp
naphthyl
ring
optim
substitut
presenc
methyl
group
aforement
stereogen
center
import
potenc
interestingli
sarscov
plpro
exhibit
signific
stereoprefer
r
enantiom
ic
ec
minim
stereochem
select
observ
enantiom
r
ic
valu
respect
ec
structur
base
high
bind
affin
inhibitor
h
also
quit
similar
xray
crystal
structur
complex
reveal
sever
hydrophob
interact
result
highli
hydrophob
naphthyl
ring
hydrogen
bond
addit
signific
conform
chang
within
activ
site
promin
apo
inhibitorbound
structur
specif
highli
mobil
gli
gli
adjac
activ
site
close
upon
inhibitor
bind
therebi
chang
orient
enzym
backbon
allow
hbond
inhibitor
core
howev
rel
conform
adopt
smaller
inhibitor
compound
requir
differ
slightli
open
conform
accommod
longer
scaffold
bulkier
ring
antivir
potenc
sarscov
plpro
inhibitor
like
yet
suffici
make
therapeut
viabl
optim
inhibitori
potenc
well
physicochem
properti
necessari
toward
goal
util
previou
sar
analysi
xray
structur
compound
complex
sarscov
plpro
develop
second
gener
plpro
inhibitor
disclos
sar
new
seri
potent
sarscov
plpro
inhibitor
select
antivir
efficaci
biolog
evalu
detail
report
molecular
interact
sarscov
plpro
inhibitor
aid
xray
crystallograph
studi
compound
establish
potent
sarscov
plpro
inhibitor
identifi
thu
far
vitro
furthermor
compound
display
effect
perturb
sarscov
replic
vero
cell
display
low
cytotox
high
select
sarscov
plpro
human
homologu
enzym
improv
resolut
sarscov
xray
structur
reveal
novel
factor
account
observ
high
bind
affin
piperidinecontain
compound
previous
elus
molecular
contribut
benzyl
substitu
carboxamid
therefor
data
highlight
well
two
slightli
less
potent
metabol
stabl
analogu
good
candid
advanc
preclin
evalu
addit
demonstr
effect
inhibit
potenti
fatal
pathogen
children
elderli
compound
relat
analogu
importantli
compound
may
also
present
opportun
develop
broaderspectrum
antivir
drug
infect
caus
sarscov
primari
ht
lead
develop
b
hit
primari
ht
develop
chiral
center
nearli
equipot
isom
deriv
hit
indic
asterisk
appropri
nitril
c
treat
grignard
reagent
intermediari
imin
hydrolyz
keton
c
acid
condit
scheme
keton
reduc
action
lah
alcohol
c
mesyl
displac
treatment
ethyl
isonipecot
provid
amino
ester
c
saponif
carboxyl
acid
follow
coupl
piperonylamin
give
final
racem
analogu
c
similar
displac
strategi
employ
obtain
hydroxyl
analogu
scheme
hydroxi
keton
reduc
lah
diol
primari
alcohol
select
protect
tertbutyldimethylsilyl
tb
ether
give
free
secondari
alcohol
mesyl
displac
ethyl
isonipecot
result
amino
ester
hydrolyz
correspond
acid
coupl
piperonylamin
provid
tbsprotect
compound
silyl
ether
remov
csf
afford
desir
hydroxi
analogu
displac
rout
use
scheme
success
hinder
phenyl
analogu
employ
lengthier
approach
previous
report
ghosh
et
al
scheme
treat
benzylmagnesium
chlorid
result
imin
hydrolyz
acid
condit
keton
reduct
amin
previous
describ
provid
amin
amin
condens
bisaldehyd
deriv
dimethyl
methyl
malon
give
dihydropyridin
dimethyl
ester
readili
reduc
piperidin
heterogen
hydrogen
diester
convert
monoest
krapcho
method
subsequ
hydrolyz
acid
coupl
piperonylamin
give
desir
analogu
prepar
r
amid
analogu
summar
scheme
start
r
ethyl
acid
prepar
accord
method
ghosh
et
al
coupl
acid
variou
arylmethylamin
arylethylamin
effect
either
edci
presenc
diea
uroniumbas
coupl
reagent
hatu
racem
quinolinyl
isoquinolinyl
analogu
gener
correspond
aldehyd
treatment
methylmagnesium
chlorid
give
methylcarbinol
scheme
altern
carbinol
prepar
addit
methylmagnesium
chlorid
follow
sodium
borohydrid
reduct
result
keton
describ
experiment
section
displac
correspond
mesyl
ethyl
isonipecot
afford
ester
scheme
saponif
follow
edcimedi
coupl
provid
final
amid
conform
restrict
analogu
prepar
outlin
scheme
reduct
amin
keton
ammonium
acet
sodium
cyanoborohydrid
provid
amin
quantit
yield
convers
piperidin
ester
effect
threestep
sequenc
analog
scheme
synthesi
quinolinyland
isoquinolinylamid
employ
scheme
saponifict
lioh
mixtur
thfmeohh
furnish
free
acid
final
amid
coupl
edci
hobt
diea
led
product
target
analogu
worth
note
shorter
ethyl
isonipecot
displac
rout
use
scheme
success
mesyl
deriv
reductionmesyl
presum
excess
steric
hindranc
relationship
analysi
compound
competit
inhibitor
sarscov
plpro
display
potent
enzymat
inhibit
ic
low
micromolar
antivir
activ
sarscov
evolv
small
sar
studi
ht
hit
figur
therefor
attract
lead
develop
antisar
drug
candid
compound
compos
central
core
decor
substitu
piperidinyl
carboxamid
nitrogen
respect
previou
sar
establish
prefer
substitut
pattern
requir
singl
methyl
substitu
methylen
linker
effect
inhibit
compar
unsubstitut
gemdimethyl
deriv
minim
stereochem
prefer
xray
crystallograph
studi
sarscov
complex
show
methyl
group
r
enantiom
extend
small
pocket
hydrophob
polar
featur
fill
water
molecul
explor
dimens
avail
pocket
substitu
well
hbond
opportun
first
set
analogu
explor
incorpor
larger
polar
substitu
oh
ome
ph
methyl
group
posit
r
tabl
addit
substitu
r
result
higher
ic
valu
substitut
loss
inhibitori
potenc
proport
substitu
size
trend
indic
correspond
pocket
might
less
access
predict
crystal
structur
clear
opportun
extra
hbond
lipophil
interact
also
appear
potenti
entrop
gain
displac
water
molecul
larger
r
group
achiev
like
larger
enthalp
penalti
break
hbond
form
water
molecul
asp
arg
tyr
thr
asp
result
unlik
previous
report
predict
fragment
map
program
ftmap
water
molecul
remov
comput
analys
demonstr
experiment
pocket
unlik
provid
extra
ligandbind
site
room
larger
substitu
next
examin
effect
incorpor
substitu
benzyl
posit
r
form
second
stereogen
carbon
use
unsubstitut
compound
ic
compar
diastereoisomer
epim
methyl
group
r
decreas
inhibitori
activ
compar
extent
ic
respect
indic
steric
clash
sarscov
plpro
interestingli
stereoprefer
observ
methoxymethyl
ic
compar
epimer
ic
could
indic
hbond
region
simpli
abil
activ
enantiom
retain
methoxi
solventexpos
environ
therebi
avoid
desolv
penalti
howev
activ
analogu
seri
surpass
effect
initi
unsubstitut
compound
surmis
substitut
posit
r
engag
activ
site
enzym
favor
interact
therefor
unlik
lead
activ
improv
previou
sar
studi
aromat
substitut
pattern
benzyl
group
limit
mand
pmethoxi
analogu
potent
lead
benzodioxolan
analogu
xray
structur
sarscov
complex
one
oxygen
within
gln
side
chain
amid
nitrogen
suggest
potenti
form
hbond
howev
poor
electron
densiti
gln
side
chain
oxygen
contribut
inhibitori
potenc
uncertain
therefor
mutat
gln
alanin
glutam
aspart
residu
purifi
mutant
enzym
determin
ic
valu
found
ic
valu
mutant
enzym
wild
type
sarscov
plpro
indic
gln
contribut
bind
via
interact
dioxolan
ring
data
shown
observ
compound
remov
dioxolan
ring
result
decreas
potenc
suggest
dioxolan
group
provid
signific
contribut
inhibitori
potenc
interact
gln
therefor
elucid
natur
interact
provid
group
benzen
ring
deriv
divers
substitu
posit
r
explor
incorpor
pethyl
group
r
improv
potenc
unsubstitut
prototyp
surpass
dioxolan
lead
compar
effect
achiev
pand
mmethylcarboxamid
deriv
ic
ic
respect
display
hbond
donor
acceptor
revers
amid
direct
acetamido
group
result
significantli
differ
activ
level
para
meta
posit
isom
ic
ic
respect
extens
acetamido
group
meta
posit
favor
previou
pair
dramat
decreas
activ
correspond
deriv
ic
revers
meta
vs
para
trend
seen
correspond
pair
chloro
deriv
ic
ic
halogen
toler
para
posit
final
deriv
featur
monofluoro
substitut
para
meta
posit
respect
display
signific
improv
valu
report
mean
standard
deviat
base
minimum
triplic
measur
surprisingli
substitut
ic
significantli
detriment
effect
decreas
inhibitori
potenc
compar
gener
neither
steric
electron
factor
invok
ration
systemat
effect
substitut
pattern
r
r
inhibitori
activ
group
divers
achiev
similar
level
activ
despit
present
wide
rang
polar
size
hbond
capac
significantli
monosubstitut
meta
posit
smallest
yet
electronwithdraw
fluoro
group
capabl
induc
dramat
polar
effect
associ
benzen
ring
result
potent
sarscov
plpro
inhibitor
identifi
thu
far
attempt
improv
solubl
potent
compound
bioisoster
naphthalen
benzen
quinolin
pyridin
respect
exploit
synthes
correspond
deriv
tabl
detriment
effect
activ
observ
upon
replac
naphthyl
ring
system
quinolin
ic
ic
isoquinolin
ic
ic
test
racem
replac
phenyl
ring
prototyp
isoster
ic
ic
decreas
potenc
order
magnitud
interestingli
activ
rescu
addit
group
ring
analogu
ic
confirm
benefit
hbond
group
aromat
ring
test
whether
gln
involv
interact
compound
determin
ic
valu
sar
plpro
mutant
enzym
gln
ala
gln
asp
gln
glu
observ
differ
ic
valu
within
experiment
error
indic
signific
interact
involv
data
shown
analysi
activ
site
potenti
hydrogenbond
residu
produc
obviou
candid
extend
separ
two
aromat
center
compound
one
carbon
atom
result
weaken
inhibit
activ
correspond
variant
ic
ic
effect
surprisingli
minor
consid
natur
perturb
perhap
indic
signific
amount
flexibl
activ
site
sarscov
plpro
region
bound
benzen
moieti
final
tricycl
analogu
prepar
conform
restrict
analogu
potent
inhibitor
figur
design
lock
conform
bond
join
naphthyl
ring
piperidinylethyl
group
observ
xray
structur
sarscov
complex
modif
howev
led
signific
loss
activ
ic
result
suggest
inhibitorinducedfit
mechan
associ
size
conform
freedom
compound
allow
optim
fit
achiev
xray
structur
analys
sarscov
plpro
bound
comparison
gain
structur
insight
enhanc
potenc
compound
sarscov
plpro
cocrystal
complex
pdb
code
pdb
code
use
approach
similar
crystal
sarsplpro
complex
result
screen
crystal
condit
diffract
qualiti
crystal
complet
xray
data
set
collect
sarscov
complex
resolut
respect
tabl
sarscov
complex
crystal
space
group
contain
two
monom
per
asymmetr
unit
identif
molecular
replac
solut
perform
initi
round
refin
sarscov
plpro
structur
model
absenc
ligand
water
strong
residu
electron
densiti
observ
f
f
c
map
activ
site
monom
within
asymmetr
unit
strong
continu
electron
densiti
inhibitor
allow
unequivoc
posit
model
within
ligandbind
site
figur
figur
bind
sarscov
plpro
activ
site
orient
figur
figur
describ
previous
compound
compound
bind
adjac
activ
site
enzym
subsit
figur
figur
exclus
interact
catalyt
triad
cy
asp
upon
inhibitor
bind
gli
gli
contain
tyr
adopt
close
conform
via
inducedfit
mechan
interact
inhibitor
enabl
format
hbond
backbon
carbonyl
tyr
carboxyamid
nitrogen
inhibitor
addit
import
interact
observ
piperidin
ring
nitrogen
side
chain
carboxyl
asp
pucker
piperidin
ring
posit
cation
nitrogen
within
distanc
oxygen
carboxyl
asp
therebi
form
chargetocharg
mediat
hbond
structur
superimposit
two
sarscov
complex
figur
show
ring
align
ident
pack
two
tandem
prolin
pro
pro
hydrophob
pocket
form
side
chain
prolin
tyr
tyr
thr
figur
figur
pocket
orient
r
methyl
group
small
caviti
line
hydrophob
hydrophil
side
chain
wherein
hbond
opportun
exist
side
chain
asp
thr
tyr
enhanc
resolut
complex
compar
complex
allow
better
placement
three
conserv
water
molecul
present
within
caviti
figur
presenc
water
molecul
increas
polar
decreas
effect
size
otherwis
larger
mostli
hydrophob
caviti
smaller
caviti
explain
observ
sar
hydrophob
polar
extens
r
methyl
posit
r
tabl
figur
chemic
structur
compound
conform
restrict
analogu
design
lock
conform
compound
conform
observ
xray
crystal
structur
sarscov
plpro
bound
wherebi
larger
group
detriment
bind
affin
observ
suggest
potenti
entrop
gain
bind
energi
displac
water
molecul
achiev
incorpor
larger
polar
substitu
enthalpi
necessari
break
hbond
water
molecul
side
chain
must
larg
overcom
superimposit
plpro
complex
shown
figur
discuss
previou
structur
comput
analys
structur
show
moieti
move
within
amid
nitrogen
gln
side
chain
howev
mutat
gln
ala
glu
asp
show
signific
chang
inhibitori
potenc
test
indic
hbond
interact
side
chain
gln
interestingli
superimposit
complex
show
near
perfect
overlap
ring
differ
posit
carboxamid
nitrogen
compar
caus
slight
tilt
orient
benzen
ring
allow
accommod
differ
benzen
substitu
result
conclud
slightli
enhanc
inhibitori
activ
compound
compar
due
abil
form
collect
stronger
van
der
waal
interact
mfluorobenzen
side
chain
tyr
slightli
stronger
interact
backbon
oxygen
atom
tyr
gln
figur
assess
potenc
select
sarscov
plpro
inhibitor
human
viral
usp
homologu
develop
enzym
inhibitor
broadspectrum
specif
attract
approach
treatment
infect
caus
current
futureemerg
human
coronavirus
howev
avoid
druginduc
toxic
potenti
side
effect
crucial
maintain
high
inhibitori
potenc
without
crossreact
critic
homologu
cellular
deubiquitin
enzym
dub
first
assess
compound
select
set
potent
analogu
test
panel
human
dub
includ
repres
ubiquitin
specif
proteas
usp
structur
similar
plpro
along
human
cystein
proteas
caspas
cathepsin
k
tabl
compound
test
inhibitori
activ
less
inhibit
report
inhibitori
activ
ic
valu
report
importantli
detect
signific
inhibit
human
dub
cystein
proteas
enzym
test
indic
plpro
inhibitor
select
unlik
signific
offtarget
activ
next
evalu
potenti
set
analogu
develop
broaderspectrum
coronavir
inhibitor
analogu
tabl
counterscreen
viral
orthologu
enzym
human
coronaviru
member
one
caus
agent
croup
children
infect
result
hospit
current
specif
treatment
individu
infect
analogu
show
inhibit
singl
dose
concentr
full
dose
respons
curv
inhibit
versu
increas
compound
concentr
determin
six
compound
includ
compound
produc
typic
dose
respons
curv
inhibit
data
fit
determin
ic
maximum
percent
inhibit
valu
tabl
result
show
inhibit
achiev
seri
compound
albeit
significantli
weaker
inhibit
sarscov
plpro
micromolar
versu
nanomolar
rang
suggest
sarscov
plpro
may
display
suffici
structur
similar
activ
site
potenti
develop
dualtarget
inhibitor
sarscov
antivir
activ
cytotox
evalu
potent
compound
compound
exhibit
lower
topolog
polar
surfac
area
tpsa
rel
initi
inhibitor
tpsa
therefor
propos
enhanc
cell
permeabl
thu
antivir
activ
rel
basi
possibl
improv
compound
along
seven
potent
analogu
two
quinolon
deriv
subject
antivir
assay
use
wellestablish
method
protocol
assay
compound
titrat
mockand
sarscovinfect
vero
cell
result
respons
curv
fit
fourparamet
logist
equat
curv
compar
mockinfect
cell
assess
druginduc
cytotox
vero
cell
line
result
ec
valu
cytotox
concentr
cc
shown
tabl
greater
potenc
test
compound
display
low
cytotox
level
cc
improv
therapeut
index
ti
valu
vero
cell
compar
compound
ic
valu
compound
display
similar
slightli
improv
antivir
activ
compar
initi
compound
howev
case
best
compound
improv
ic
valu
addit
improv
antivir
activ
observ
ec
compar
metabol
stabil
plasma
bind
studi
ultim
goal
achiev
protect
coronavir
infect
vivo
evalu
stabil
best
new
analogu
phase
metabol
mous
liver
microsom
tabl
lead
compound
prove
exceedingli
unstabl
complet
consum
within
min
entir
unexpect
presenc
moieti
render
benzyl
aromat
ring
electronrich
known
target
cytochrom
somewhat
surprisingli
much
electronpoor
still
metabol
rapidli
suggest
metabol
occur
distal
benzylamid
consist
hypothesi
less
lipophil
bi
amid
methoxypyridin
significantli
stabl
parent
drug
remain
min
respect
halfliv
longer
bind
antivir
drug
human
serum
protein
may
result
reduc
antivir
activ
evalu
plasma
bind
abil
compound
tabl
measur
shift
ic
valu
variou
concentr
human
plasma
protein
serum
shift
assay
observ
signific
chang
ic
valu
compound
serum
shift
assay
perform
presenc
human
serum
albumin
hsa
data
shown
abund
protein
human
plasma
mgml
observ
suggest
specif
interact
compound
hsa
take
place
secondgener
seri
highli
potent
sarscov
plpro
inhibitor
design
evalu
biolog
advanc
anticoronaviru
drug
develop
four
compound
found
potent
sarscov
plpro
inhibit
sarscov
antivir
activ
potent
first
gener
inhibitor
none
five
compound
exhibit
cytotox
offtarget
inhibitori
activ
seri
human
dub
cystein
proteas
enzym
five
inhibitor
bind
human
serum
albumin
hsa
secondgener
compound
exhibit
significantli
improv
metabol
stabil
compar
although
compound
potent
sarscov
plpro
inhibitor
ic
effect
antivir
compound
cell
cultur
ec
significantli
less
metabol
stabl
compar
compound
similarli
effect
inhibit
sarscov
plpro
ic
ic
inhibit
sarscov
infect
vero
cell
ec
ec
thu
compound
like
better
candid
advanc
anim
efficaci
model
final
high
resolut
inhibitorbound
crystal
structur
plpro
reveal
novel
aspect
inhibitor
bind
mode
provid
guidanc
optim
plpro
inhibitor
h
nmr
c
nmr
spectra
record
part
per
million
ppm
scale
intern
standard
residu
tetramethylsilan
ppm
rotam
describ
ratio
rotam
rotam
b
possibl
otherwis
rotam
distinguish
nmr
peak
describ
multiplet
mass
spectrometri
data
obtain
water
corpor
lct
puriti
test
compound
assess
hplc
use
agil
seri
agil
zorbax
eclips
plu
column
nm
detect
follow
gradient
acnwat
min
acnwat
min
acn
water
min
valu
compound
includ
end
experiment
procedur
pure
hplc
retent
time
r
record
minut
min
na
sodium
sulfat
nahco
sodium
bicarbon
na
co
sodium
carbon
cs
co
cesium
carbon
nh
cl
ammonium
chlorid
k
co
potassium
carbon
koh
potassium
hydroxid
hcl
hydrogen
chlorid
naoh
sodium
hydroxid
lioh
lithium
hydroxid
lah
lithium
aluminum
hydrid
etoh
ethanol
nacn
sodium
cyanid
et
diethyl
ether
csf
cesium
fluorid
nacl
sodium
chlorid
tbscl
tertbutyldimethylsilyl
chlorid
ms
methanesulfon
anhydrid
mscl
methanesulfonyl
chlorid
acoh
acet
acid
nabh
sodium
borohydrid
nabh
cn
sodium
cyanoborohydrid
h
hydrogen
n
nitrogen
ms
molecular
siev
assay
abbrevi
follow
luc
luciferas
mtt
bromid
addit
abbrevi
follow
aq
aqueou
satur
satur
rt
room
temperatur
anhydr
reaction
run
atmospher
dri
nitrogen
n
benzo
propyl
ethyl
propyl
mg
mmol
dissolv
mixtur
aqueou
naoh
total
volum
ml
stir
h
mixtur
allow
cool
organ
solvent
mixtur
mostli
remov
rotari
evapor
ph
reduc
addit
concentr
hcl
result
white
precipit
collect
filter
give
desir
carboxyl
acid
mg
without
purif
follow
ad
sequenti
anhydr
dmf
ml
molecular
siev
propyl
acid
mg
mmol
diea
ml
mmol
edci
mg
mmol
hobt
mg
mmol
final
piperonylamin
ml
mmol
stir
room
temperatur
h
time
materi
partit
na
co
solut
etoac
organ
layer
wash
na
co
solut
ml
brine
ml
organ
layer
dri
anhydr
mgso
filter
concentr
vacuo
purif
accomplish
via
flash
chromatographi
g
silica
redisep
gold
column
combiflash
elut
etoac
hex
give
desir
product
mg
n
benzo
ethyl
silyl
ether
mg
mmol
dissolv
acn
ml
h
ml
ad
csf
mg
mmol
mixtur
stir
room
temperatur
h
mixtur
partit
aqueou
na
co
ml
etoac
ml
extract
extract
dri
anhydr
mgso
filter
concentr
vacuo
residu
purifi
flash
chromatographi
amineactiv
silica
redisep
column
etoachex
give
final
product
mg
ethyl
ethyl
mg
mmol
dissolv
etoh
ml
naoh
ml
stir
h
ph
drop
dropwis
addit
concentr
hcl
materi
extract
etoacet
ml
solvent
dri
anhydr
mgso
filter
remov
vacuo
give
ethyl
acid
mg
without
purif
follow
ad
sequenti
anhydr
dmf
ml
molecular
siev
ethyl
acid
mg
mmol
diea
ml
mmol
edci
mg
mmol
hobt
mg
mmol
final
piperonylamin
ml
mmol
stir
room
temperatur
h
time
materi
partit
aqueou
na
co
solut
etoac
organ
layer
wash
aqueou
na
co
solut
ml
brine
ml
organ
layer
dri
anhydr
mgso
filter
concentr
vacuo
materi
purifi
via
alumina
flash
chromatographi
g
basic
alumina
redisep
cartridg
etoachex
give
final
desir
compound
mg
mmol
dissolv
mixtur
aqueou
naoh
total
volum
ml
stir
h
mixtur
allow
cool
ph
reduc
addit
concentr
hcl
result
white
precipit
collect
filter
give
acid
mg
white
powder
follow
ad
sequenti
anhydr
dmf
ml
molecular
siev
acid
mg
mmol
diea
mmol
edci
mg
mmol
hobt
mg
mmol
piperonylamin
mmol
stir
room
temperatur
h
time
materi
partit
aqueou
na
co
solut
etoac
organ
layer
wash
aqueou
na
co
solut
ml
brine
ml
organ
layer
dri
anhydr
mgso
filter
concentr
vacuo
residu
purifi
flash
chromatographi
g
silica
etoachex
n
ethyl
ethyl
ethyl
g
mmol
dissolv
methanol
ml
follow
addit
n
sodium
hydroxid
ml
mmol
one
portion
result
mixtur
stir
h
room
temperatur
concentr
vacuo
partit
ether
minimum
amount
water
layer
separ
aqueou
layer
treat
acoh
dropwis
solut
acid
ph
paper
solut
concentr
vacuo
dri
high
vacuum
overnight
room
temperatur
result
acid
use
without
purif
solut
r
ethyl
acid
g
mmol
dri
dmf
ml
ad
edci
g
mmol
hobt
g
mmol
diea
ml
mmol
follow
methanamin
g
mmol
reaction
mixtur
stir
overnight
room
temperatur
dilut
satur
nahco
extract
etoac
combin
organ
layer
wash
satur
nacl
dri
mgso
concentr
purifi
silica
flash
chromatographi
meohdcm
obtain
g
yield
n
ethyl
ethyl
ethyl
g
mmol
dissolv
methanol
ml
follow
n
sodium
hydroxid
ml
mmol
one
portion
result
mixtur
stir
h
room
temperatur
concentr
vacuo
partit
ether
minimum
amount
water
layer
separ
aqueou
layer
treat
acoh
dropwis
solut
measur
acid
ph
paper
solut
concentr
vacuo
dri
high
vacuum
result
carboxyl
acid
use
without
purif
next
step
solut
r
ethyl
acid
g
mmol
dri
dmf
ml
ad
edci
g
mmol
hobt
g
mmol
diea
ml
mmol
follow
methanamin
g
mmol
mixtur
stir
overnight
room
temperatur
dilut
satur
nahco
extract
etoac
combin
organ
layer
wash
satur
nacl
dri
mgso
concentr
purifi
silica
gel
flash
chromatographi
meohdcm
provid
target
compound
g
colorless
oil
wash
na
co
ml
organ
layer
dri
mgso
filter
filtrat
concentr
vacuo
residu
purifi
flash
chromatographi
g
silica
etoachex
gradient
give
desir
product
mg
ethanon
mg
mmol
prepar
previous
literatur
method
dissolv
anhydr
thf
ml
cool
ice
bath
lah
thf
ml
mmol
slowli
ad
dropwis
solut
mixtur
allow
warm
room
temperatur
stir
h
time
reaction
work
fieser
method
aluminum
filter
filtrat
solvent
remov
vacuo
give
white
solid
purifi
flash
chromatographi
g
silica
etoachex
give
desir
product
mg
white
solid
ethyl
tertbutyldimethylsilyl
oxi
ethyl
tertbutyldimethylsilyl
oxi
ethanol
mg
mmol
dissolv
dcm
ml
molecular
siev
follow
diea
ml
mmol
mscl
ml
mmol
ad
dropwis
mixtur
allow
stir
room
temperatur
h
ethyl
ml
mmol
ad
dropwis
mixtur
stir
h
room
temperatur
solut
et
oetoac
ml
ad
solut
wash
aqueou
aqueou
na
co
ml
brine
ml
dri
anhydr
mgso
filter
filtrat
concentr
vacuo
crude
residu
purifi
flash
chromatographi
g
silica
etoachex
give
desir
product
mg
oil
n
benzo
tertbutyldimethylsilyl
oxi
ethyl
ethyl
tertbutyldimethylsilyl
oxi
ethyl
mg
mmol
dissolv
ethanol
ml
aqueou
naoh
ml
stir
h
mixtur
cool
acidifi
concentr
hcl
result
white
precipit
collect
filter
dri
high
vacuum
overnight
give
desir
carboxyl
acid
mg
white
powder
crude
solid
ad
solut
diea
ml
mmol
edci
mg
mmol
hobt
mg
mmol
anhydr
dmf
ml
molecular
siev
piperonylamin
ml
mmol
ad
mixtur
allow
stir
h
room
temperatur
time
solut
et
oetoac
ml
ad
wash
aqueou
na
co
ml
brine
ml
dri
anhydr
mgso
concentr
vacuo
crude
oil
purifi
flash
chromatographi
g
silica
etoachex
give
desir
product
mg
oil
g
mmol
dissolv
anhydr
et
ml
dri
glasswar
follow
addit
benzylmagnesium
chlorid
ml
mmol
n
stir
room
temperatur
h
time
hcl
ad
ml
mixtur
stir
min
time
necessari
add
et
allow
cool
room
temperatur
point
materi
extract
etoacet
dri
anhydr
mgso
filtrat
concentr
vacuo
result
residu
purifi
flash
chromatographi
g
silica
etoachex
give
desir
keton
g
dimethyl
dicarboxyl
dimethyl
methyl
malon
mg
mmol
dissolv
mixtur
thf
ml
aqueou
hcl
ml
stir
room
temperatur
h
time
reaction
neutral
solid
nahco
solut
mg
mmol
prepar
previous
literatur
method
thf
ml
ad
mixtur
stir
room
temperatur
h
time
solut
extract
etoac
ml
combin
extract
dri
anhydr
mgso
filtrat
concentr
vacuo
residu
purifi
via
flash
chromatographi
g
silica
etoachex
give
desir
condens
product
mg
yellow
oil
dimethyl
dimethyl
dicarboxyl
mg
mmol
dissolv
n
sparg
meoh
ml
pdc
ad
mix
psi
h
h
room
temperatur
filter
celit
filtrat
concentr
vacuo
give
desir
product
mg
without
purif
ethanol
solut
g
mmol
dri
thf
n
ad
methylmagnesium
chlorid
ml
mmol
dropwis
result
mixtur
stir
min
warm
room
temperatur
nh
cl
ad
mixtur
stir
min
dilut
etoacet
wash
satur
nacl
dri
mgso
residu
purifi
flash
chromatographi
etoachex
afford
desir
compound
g
ethanol
solut
g
mmol
dri
thf
n
ad
methylmagnesium
chlorid
ml
mmol
dropwis
result
mixtur
stir
min
warm
room
temperatur
satur
aqueou
nh
cl
ad
mixtur
stir
min
dilut
etoacet
wash
satur
nacl
dri
mgso
residu
purifi
silica
flash
chromatographi
etoachex
afford
target
compound
g
yellow
oil
ethanol
solut
g
mmol
dri
thf
n
ad
methylmagnesium
chlorid
ml
mmol
dropwis
result
mixtur
stir
min
warm
room
temperatur
satur
aqueou
nh
cl
ad
mixtur
stir
min
dilut
etoacet
organ
layer
wash
satur
nacl
dri
mgso
concentr
provid
white
solid
tritur
ether
filter
dri
high
vacuum
give
ethanol
g
yield
ethanol
solut
mg
mmol
dri
et
ml
ml
memgbr
mmol
ad
allow
stir
h
produc
bright
orang
solut
reaction
quench
h
ml
hcl
ml
stir
h
solut
basifi
satur
nahco
extract
et
ml
dri
mgso
concentr
vacuo
residu
purifi
silca
flash
chromatographi
etoachex
furnish
ethanon
mg
yellow
oil
compound
mg
mmol
dissolv
meoh
ml
nabh
ad
mixtur
allow
stir
h
mixtur
concentr
vacuo
treat
satur
aqueou
nh
cl
solut
extract
dcm
ml
dri
mgso
concentr
vacuo
residu
purifi
silica
flash
chromatographi
etoachex
furnish
desir
compound
mg
clear
oil
ethyl
ethyl
solut
ethanol
g
mmol
dri
dcm
ad
diea
g
mmol
follow
ms
g
mmol
result
mixtur
stir
min
ethyl
g
determin
ic
valu
select
compound
describ
except
assay
contain
hsa
mgml
counterscreen
assay
select
dub
usp
cystein
proteas
counterscreen
assay
perform
reaction
volum
includ
nm
enzym
compound
rlrggamc
substrat
assay
buffer
mm
hepe
ph
mgml
bsa
mm
dtt
assay
perform
triplic
inhibitor
enzym
activ
monitor
describ
counterscreen
human
usp
cystein
proteas
determin
use
purifi
enzym
avail
progenra
inc
part
dub
screen
servic
assay
perform
triplic
use
compound
ubrhodamin
substrat
usp
commerci
avail
fluorogen
peptid
substrat
caspas
cathepsin
k
antivir
cytotox
assay
sarscov
antivir
activ
infect
vero
cell
perform
previous
describ
laboratori
briefli
vero
cell
seed
cultur
plate
cell
per
well
h
prior
infect
sarscov
cell
mock
sarscov
infect
h
presenc
increas
concentr
compound
upon
incub
cell
viabil
determin
use
cell
titerglo
luminesc
cell
viabil
assay
promega
experi
perform
twice
triplic
half
maxim
effect
concentr
ec
cytostat
concentr
cc
valu
calcul
use
fourparamet
logist
equat
mean
sigma
plot
graphpad
prism
softwar
cultur
cell
viabil
measur
hek
cell
perform
describ
triplic
h
compound
addit
liver
metabol
studi
compound
incub
mous
liver
microsom
mgml
nadph
phosphat
buffer
previous
describ
mutagenesi
gln
mutagenesi
gln
ala
glu
asp
perform
quickchang
sitedirect
mutagenesi
describ
zhen
et
al
mutant
enzym
purifi
describ
wildtyp
sarsplpro
enzym
crystal
sarscov
plpro
complex
inhibitor
prior
crystal
untag
sarscov
plpro
mm
tri
ph
mm
nacl
mm
dtt
concentr
mgml
incub
mm
inhibitor
dissolv
dmso
ethanol
ad
dilut
incub
overnight
crystal
perform
use
sittingdrop
vapordiffus
method
mix
equal
amount
proteininhibitor
reservoir
solut
contain
mm
sodium
citrat
ph
vv
peg
crystal
soak
cryosolut
consist
reservoir
solut
mm
inhibitor
glycerol
crystal
flashfrozen
liquid
nitrogen
store
synchrotron
time
avail
crystal
transfer
liquid
nitrogen
stream
dri
nitrogen
ga
k
xray
data
collect
xray
data
collect
life
sciencescollabor
access
team
lscat
beamlin
advanc
photon
sourc
argonn
nation
laboratori
data
process
scale
use
sarscov
complex
crystal
two
monom
asymmetr
unit
crystal
belong
space
group
unit
cell
dimens
b
c
inhibitorbound
structur
diffract
resolut
respect
initi
phase
determin
molecular
replac
solut
use
sarscov
inhibitor
complex
structur
search
model
molrep
program
suit
model
build
refin
perform
use
program
refmac
phenix
coot
final
xray
data
process
refin
statist
summar
tabl
